

ORPHAN MEDICAL INC  
Form 8-K  
February 22, 2005

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **February 16, 2005**

## ORPHAN MEDICAL, INC.

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-24760**  
(Commission file number)

**41-1784594**  
(I.R.S. employer identification number)

**Suite 250,**  
**13911 Ridgedale Drive,**  
**Minnetonka, MN**  
(Address of principal executive  
offices)

**55305**  
(zip code)

**(952) 513-6900**  
(Registrant's telephone number,  
including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

## Edgar Filing: ORPHAN MEDICAL INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 16, 2005, Orphan Medical issued a press release discussing fourth quarter and full-year 2004 results. The press release is included as Exhibit 99.1 hereto and is incorporated herein by reference. The press release contains forward-looking statements regarding the Company and includes a cautionary statement identifying important factors that could cause actual results to differ materially from those anticipated.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 22, 2004

ORPHAN MEDICAL, INC.

/s/ Timothy G. McGrath  
Timothy G. McGrath  
Chief Financial Officer  
(duly authorized officer and  
principal financial officer)

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated February 16, 2004.